A Phase III Randomized Trial of Gemcitabine Cisplatin and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers

Brief description of study

If you have been newly diagnosed with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer), you may qualify to participate in this study. The main purpose of this phase III trial is to evaluate the investigational drug, nab-Paclitaxel (a microtubule inhibitor) in combination with Gemcitabine (nucleoside analog) and cisplatin (interferes with DNA replication) vs. gemcitabine and cisplatin only. The study will evaluate how well you do on either regimen.

Clinical Study Identifier: s19-00539
ClinicalTrials.gov Identifier: NCT03768414
Principal Investigator: Nina Beri.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.